Literature DB >> 2725703

Inhibition of the 5-HT-induced cardiogenic hypertensive chemoreflex by the selective 5-HT3 receptor antagonist ICS 205-930.

H Berthold1, G Scholtysik, G Engel.   

Abstract

We investigated the effect of ICS 205-930 [(3 alpha-tropanyl)-1H-indole-3-carboxylic acid ester], a selective antagonist at 5-HT3 receptors, on the cardiogenic hypertensive chemoreflex in the anaesthetized dog. The reflex was elicited by injection of 5-HT (12.5-1600 micrograms) into the left cardiac ventricle and consisted of a dose-dependent systemic hypertension associated with a decrease in heart rate. ICS 205-930 (10, 30, and 100 micrograms/kg i.v.) caused a displacement to the right of both the dose-response curves of 5-HT-induced blood pressure increase and heart rate reduction. Its blocking effects upon the action of 5-HT could be surmounted by increasing the dose of the agonist. The selective 5-HT2 receptor antagonist, ketanserin (0.1 mg/kg i.v.) and the combined 5-HT1 and 5-HT2 receptor antagonist, methiothepin (0.1 mg/kg i.v.) had no influence on the hypertensive reflex. When the reflex was elicited by the ganglionic stimulant, 1,1-dimethyl-4-phenyl-piperazinium (DMPP; 100-1600 micrograms), ICS 205-930 had no blocking effect. The results suggest that the 5-HT-induced cardiogenic hypertensive chemoreflex is mediated by 5-HT3 receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2725703     DOI: 10.1007/bf00173574

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  Analysis of components in a cardiogenic hypertensive chemoreflex.

Authors:  T N James; J H Isobe; F Urthaler
Journal:  Circulation       Date:  1975-08       Impact factor: 29.690

2.  Chemoreceptors of the heart.

Authors:  T N James; F Urthaler; G R Hageman
Journal:  Trans Am Clin Climatol Assoc       Date:  1977

Review 3.  Circulatory changes during the pain of angina pectoris. 1772-1965--a critical review.

Authors:  J W Roughgarden; E V Newman
Journal:  Am J Med       Date:  1966-12       Impact factor: 4.965

4.  Identification of left coronary blood supply of aortic bodies in anesthetized dogs.

Authors:  R W Eckstein; F Shintani; H E Rowen; K Shimomura; N Oya
Journal:  J Appl Physiol       Date:  1971-04       Impact factor: 3.531

5.  Cyproheptadine blockade of a cardiogenic hypertensive chemoreflex.

Authors:  G R Hageman; F Urthaler; T N James
Journal:  Proc Soc Exp Biol Med       Date:  1977-04

Review 6.  Prejunctional effects of 5-hydroxytryptamine on noradrenergic nerves in the cardiovascular system.

Authors:  P P Humphrey; W Feniuk; A D Watts
Journal:  Fed Proc       Date:  1983-02

7.  Neural pathways of a cardiogenic hypertensive chemoreflex.

Authors:  G R Hageman; F Urthaler; T N James
Journal:  Am J Physiol       Date:  1978-09

8.  Mechanism of the indirect sympathomimetic effect of 5-hydroxytrypt-amine on the isolated heart of the rabbit.

Authors:  J R Fozard; G M Mwaluko
Journal:  Br J Pharmacol       Date:  1976-05       Impact factor: 8.739

9.  MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors.

Authors:  J R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-05       Impact factor: 3.000

10.  The effects of ICS 205-930, a 5-HT antagonist, on arrhythmias and catecholamine release during canine myocardial ischaemia and reperfusion.

Authors:  S J Coker; H G Dean; K A Kane; J R Parratt
Journal:  Eur J Pharmacol       Date:  1986-08-15       Impact factor: 4.432

View more
  2 in total

1.  Cardiovascular stability with rapid intravenous infusion of ondansetron.

Authors:  J S Heyman; M L Young; R J Bagshaw; W J Levy; R T Geer; S J Aukburg; A F Joslyn; T J Conahan
Journal:  Can J Anaesth       Date:  1993-05       Impact factor: 5.063

Review 2.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.